Sharon Rosenzweig-Lipson

Summary

Affiliation: Wyeth Research
Country: USA

Publications

  1. pmc Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells
    Jie Xu
    Cardiology Research Laboratory, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
    Am J Pathol 161:2209-18. 2002
  2. ncbi Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist
    Derek C Cole
    Chemical and Screening Sciences, Wyeth Research, 401 N Middletown Road, Pearl River, New York 10965, USA
    J Med Chem 50:5535-8. 2007
  3. doi 5-HT2C receptor agonists as an innovative approach for psychiatric disorders
    Sharon Rosenzweig-Lipson
    Wyeth Discovery Neuroscience, Princeton, New Jersey 08543, USA
    Drug News Perspect 20:565-71. 2007
  4. ncbi Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503
    Sharon Rosenzweig-Lipson
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543 8000, USA
    Brain Res 1073:240-51. 2006
  5. ncbi Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents
    Sharon Rosenzweig-Lipson
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543, USA
    Psychopharmacology (Berl) 192:159-70. 2007
  6. doi Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist
    Robert H Ring
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    Neuropharmacology 58:69-77. 2010
  7. doi WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity
    Julie A Brennan
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    J Pharmacol Exp Ther 332:190-201. 2010
  8. doi The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists
    Wayne E Childers
    Chemical Sciences, Pfizer Global Research and Development, Princeton, New Jersey 08543 8000, USA
    J Med Chem 53:4066-84. 2010
  9. doi Angiotensin IV elevates oxytocin levels in the rat amygdala and produces anxiolytic-like activity through subsequent oxytocin receptor activation
    Chad E Beyer
    Pfizer Global Research and Development CN8000, Princeton, NJ, 08543 8000, USA
    Psychopharmacology (Berl) 209:303-11. 2010
  10. doi Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders
    Sarah K Leonard
    Depression and Anxiety Disorders, Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    Psychopharmacology (Berl) 197:601-11. 2008

Detail Information

Publications37

  1. pmc Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells
    Jie Xu
    Cardiology Research Laboratory, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
    Am J Pathol 161:2209-18. 2002
    ..Thus, major 5-HT Erk 1/2 signaling beyond that controlled by 5-HT(2)Rs must involve other serotonin receptor types and/or secondary signaling events...
  2. ncbi Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist
    Derek C Cole
    Chemical and Screening Sciences, Wyeth Research, 401 N Middletown Road, Pearl River, New York 10965, USA
    J Med Chem 50:5535-8. 2007
    ....
  3. doi 5-HT2C receptor agonists as an innovative approach for psychiatric disorders
    Sharon Rosenzweig-Lipson
    Wyeth Discovery Neuroscience, Princeton, New Jersey 08543, USA
    Drug News Perspect 20:565-71. 2007
    ..The current review highlights the underlying complexities of this area and provides the rationale for using 5-HT(2C) agonists in the treatment of both schizophrenia and depressive disorders...
  4. ncbi Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503
    Sharon Rosenzweig-Lipson
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543 8000, USA
    Brain Res 1073:240-51. 2006
    ....
  5. ncbi Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents
    Sharon Rosenzweig-Lipson
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543, USA
    Psychopharmacology (Berl) 192:159-70. 2007
    ..Activation of one or more of the serotonin (5-HT) receptors may play a role in mediating the antidepressant effects of SSRIs...
  6. doi Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist
    Robert H Ring
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    Neuropharmacology 58:69-77. 2010
    ..A selective OTR antagonist also failed to block the effects of OT on immobility in the TST. The significance of these findings for shaping the clinical development of OTR agonists is discussed...
  7. doi WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity
    Julie A Brennan
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    J Pharmacol Exp Ther 332:190-201. 2010
    ..Furthermore, WS-50030 provides a tool to further explore how combining these mechanisms might differentiate from other antipsychotics or antidepressants...
  8. doi The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists
    Wayne E Childers
    Chemical Sciences, Pfizer Global Research and Development, Princeton, New Jersey 08543 8000, USA
    J Med Chem 53:4066-84. 2010
    ....
  9. doi Angiotensin IV elevates oxytocin levels in the rat amygdala and produces anxiolytic-like activity through subsequent oxytocin receptor activation
    Chad E Beyer
    Pfizer Global Research and Development CN8000, Princeton, NJ, 08543 8000, USA
    Psychopharmacology (Berl) 209:303-11. 2010
    ....
  10. doi Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders
    Sarah K Leonard
    Depression and Anxiety Disorders, Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    Psychopharmacology (Berl) 197:601-11. 2008
    ..Neuropeptide S (NPS) and its receptor (NPSR) comprise a recently deorphaned G protein-coupled receptor system. Recent reports implicate NPS in the mediation of anxiolytic-like activity in rodents...
  11. ncbi Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects
    Jessica E Malberg
    Wyeth Research, Discovery Neuroscience, Princeton, NJ, USA
    Neuropsychopharmacology 32:2360-8. 2007
    ..The present studies demonstrate that an IGFBP inhibitor mimics the behavioral effects of IGF-I and that IGFBP inhibition may represent a novel mechanism by which to increase IGF-I to treat depression and anxiety...
  12. ncbi WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity
    Karen L Marquis
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543, USA
    J Pharmacol Exp Ther 320:486-96. 2007
    ..p.). Thus, the profile of the 5-HT2C selective receptor agonist WAY-163909 is similar to that of an atypical antipsychotic and additionally may have rapid onset properties...
  13. doi Preclinical characterization of BRL 44408: antidepressant- and analgesic-like activity through selective alpha2A-adrenoceptor antagonism
    Jason M Dwyer
    Discovery Neuroscience, Wyeth Research, Princeton, NJ 08543 8000, USA
    Int J Neuropsychopharmacol 13:1193-205. 2010
    ..This preclinical characterization of the neurochemical and behavioural profile of BRL 44408 suggests that selective antagonism of alpha2A-adrenoceptors may represent an effective treatment strategy for mood disorders and visceral pain...
  14. doi WAY-200070, a selective agonist of estrogen receptor beta as a potential novel anxiolytic/antidepressant agent
    Zoe A Hughes
    Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    Neuropharmacology 54:1136-42. 2008
    ....
  15. doi The orphan GPCR, GPR88, modulates function of the striatal dopamine system: a possible therapeutic target for psychiatric disorders?
    Sheree F Logue
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543, USA
    Mol Cell Neurosci 42:438-47. 2009
    ..Antipsychotic administration to Gpr88KOs normalized the PPI deficit and blocked AICS. The modulatory role of Gpr88 in striatal dopamine function suggests it may be a new target for treatments for psychiatric disorders...
  16. ncbi Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications
    Robert H Ring
    Depression and Anxiety Disorders, Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    Psychopharmacology (Berl) 185:218-25. 2006
    ..Notably, evidence from studies in females has revealed an important role for OT in regulating anxiety behavior...
  17. ncbi Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon
    S Johannes R Rajarao
    Depression and Anxiety Research, Discovery Neuroscience, Wyeth Research, CN8000, Princeton, NJ 08543, USA
    Neuropeptides 41:307-20. 2007
    ..Moreover, these data indicate rodent GALR1 receptors do not mediate galnon's in vivo activity...
  18. ncbi Differentiating antidepressants of the future: efficacy and safety
    Sharon Rosenzweig-Lipson
    Wyeth Discovery Neuroscience, Depression and Anxiety, CN 8000, Princeton, NJ 08543, USA
    Pharmacol Ther 113:134-53. 2007
    ..This review will discuss the many facets of differentiation and potential strategies for the development of novel antidepressants...
  19. ncbi Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466
    Lee E Schechter
    Discovery Neuroscience, Wyeth Research, Princeton, NJ 08543 8000, USA
    Neuropsychopharmacology 33:1323-35. 2008
    ....
  20. doi Acid sensing ion channel (ASIC) inhibitors exhibit anxiolytic-like activity in preclinical pharmacological models
    Jason M Dwyer
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ, 08543 8000, USA
    Psychopharmacology (Berl) 203:41-52. 2009
    ..Of particular interest is ASIC1a, which is located in areas associated with fear and anxiety behaviors. Recent reports suggest a role for ASIC1a in preclinical models of fear conditioning and anxiety...
  21. doi Inhibition of uptake 2 (or extraneuronal monoamine transporter) by normetanephrine potentiates the neurochemical effects of venlafaxine
    Zia Rahman
    Wyeth Research, Discovery Neuroscience, Depression and Anxiety Disorders, CN 8000, Princeton, NJ 08543 8000, USA
    Brain Res 1203:68-78. 2008
    ....
  22. ncbi WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity
    John Dunlop
    Discovery Neuroscience, Wyeth Research, Princeton, NJ 08543, USA
    J Pharmacol Exp Ther 313:862-9. 2005
    ..4 and 5.19 mg/kg i.p., respectively, consistent with the potential utility of 5-HT(2C) receptor agonists as anti-obesity agents...
  23. pmc Innovative approaches for the development of antidepressant drugs: current and future strategies
    Lee E Schechter
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, New Jersey 08543, USA
    NeuroRx 2:590-611. 2005
    ..The present review addresses the most exciting approaches and reviews the localization, neurochemical and behavioral data that provide the supporting rationale for each of these targets or target combinations...
  24. doi The 5-HT(2C) receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test
    Rachel Navarra
    Discovery Neuroscience, CN8000, Princeton, NJ 08543, USA
    Behav Brain Res 188:412-5. 2008
    ..WAY-163909 treatment selectively and dose-dependently decreased impulsivity suggesting that agonism of the 5-HT(2C) receptor may be useful for modulating impulsivity in disease states where impulsivity is a pathological feature...
  25. ncbi Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications
    John Dunlop
    Discovery Neuroscience, Wyeth Research, Princeton, NJ 08543, USA
    CNS Drug Rev 12:167-77. 2006
    ..Consistent with a potential therapeutic utility in obesity, schizophrenia and depression WAY-163909 was found to have robust dose-dependent effects in animal models of obesity, psychotic-like behavior or depression...
  26. doi ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities
    Feng Liu
    Wyeth Neuroscience Discovery Research, Princeton, New Jersey, USA
    J Pharmacol Exp Ther 327:827-39. 2008
    ..p.) in rats. Taken together, these effects are consistent with the hypothesis that allosteric potentiation of mGlu5 may provide a novel approach for development of antipsychotic and procognitive agents...
  27. doi Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405)
    Warren D Hirst
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543, USA
    J Pharmacol Exp Ther 325:134-45. 2008
    ..These results further support the rationale for use of this compound class in the treatment of cognitive dysfunction associated with psychiatric and neurological conditions...
  28. ncbi Alpha 2A-adrenoceptors enhance the serotonergic effects of fluoxetine
    Chad E Beyer
    Depression and Anxiety Research, Discovery Neuroscience, Wyeth Research, Princeton, NJ 08543, USA
    Eur J Pharmacol 539:164-7. 2006
    ..c.), respectively, did not similarly alter biogenic amine levels. Collectively, these results reveal a specific role for the alpha(2A)-adrenoceptor subtype in augmenting the neurochemical effects of antidepressants...
  29. ncbi Cycloalkyl[b][1,4]benzodiazepinoindoles are agonists at the human 5-HT2C receptor
    Annmarie L Sabb
    Chemical and Screening Sciences, Wyeth Research, CN 8000, Princeton, NJ 08543 8000, USA
    Bioorg Med Chem Lett 14:2603-7. 2004
    ..In addition, WAY-629 was active in vivo in a rat model of feeding behavior. An SAR study based on WAY-629 led to compound 11 (K(i) 13 nM, E(max) 102%)...
  30. ncbi A novel approach for predicting antidepressant-induced sexual dysfunction in rats
    Stacey J Sukoff Rizzo
    Depression and Anxiety Research, Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543 8000, USA
    Psychopharmacology (Berl) 195:459-67. 2008
    ..Sexual dysfunction is associated with antidepressant discontinuation. Therefore, there is a need for models that predict antidepressant-induced sexual dysfunction...
  31. doi The supra-additive hyperactivity caused by an amphetamine-chlordiazepoxide mixture exhibits an inverted-U dose response: negative implications for the use of a model in screening for mood stabilizers
    Michele P Kelly
    Department of Neuroscience, Discovery Research, Wyeth, Princeton, NJ 08852, USA
    Pharmacol Biochem Behav 92:649-54. 2009
    ..We argue that these data, in addition to other practical and theoretical concerns surrounding the model, limit the utility of the AMPH-CDP mixture model in drug discovery...
  32. doi Schedule-induced polydipsia: a rat model of obsessive-compulsive disorder
    Brian Platt
    Wyeth Research, Princeton, New Jersey, USA
    Curr Protoc Neurosci . 2008
    ..This protocol describes a rat SIP model of OCD and provides preclinical data for drugs that decrease polydipsia and are clinically effective in the treatment of OCD...
  33. doi 5-HT(1A) receptor antagonism reverses and prevents fluoxetine-induced sexual dysfunction in rats
    Stacey J Sukoff Rizzo
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543, USA
    Int J Neuropsychopharmacol 12:1045-53. 2009
    ..Taken together, these data suggest that 5-HT(1A) antagonist treatment may have utility for the management of SSRI-induced sexual dysfunction...
  34. ncbi Effects of the N-methyl-D-aspartate receptor antagonist perzinfotel [EAA-090; [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid] on chemically induced thermal hypersensitivity
    Michael R Brandt
    Neuroscience Discovery Research, Wyeth Research, Princeton, New Jersey, USA
    J Pharmacol Exp Ther 313:1379-86. 2005
    ..Collectively, these studies demonstrate that perzinfotel has therapeutic ratios for effectiveness versus adverse effects superior to those seen with other competitive and uncompetitive NMDA receptor antagonists studied...
  35. doi WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics
    Steven M Grauer
    Discovery Neuroscience, Wyeth Research, CN 8000, Princeton, NJ 08543, USA
    Psychopharmacology (Berl) 204:37-48. 2009
    ....
  36. doi Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists
    Ronald C Bernotas
    Chemical Sciences, Wyeth Research, 500 Arcola Road, Collegeville, PA 19426, USA
    Bioorg Med Chem 17:5153-63. 2009
    ..This compound also reduced adjunctive drinking behavior in the rat schedule-induced polydipsia assay, possibly predictive of efficacy in obsessive compulsive disorder and other anxiety related disorders...
  37. pmc Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments
    Darrick T Balu
    Department of Pharmacology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Brain Res 1211:37-43. 2008
    ....